Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.

@article{Buchanan2012AsenapineVO,
  title={Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.},
  author={Robert Williams Buchanan and John Panagides and Jun Zhao and Phillip Phiri and Wil den Hollander and Xianwei Ha and Alex Koam{\'e} Kouassi and Larry D. Alphs and Nina Schooler and Armin Szegedi and Pilar Cuesta Cazorla},
  journal={Journal of clinical psychopharmacology},
  year={2012},
  volume={32 1},
  pages={
          36-45
        }
}
Two randomized, double-blind, 26-week core studies (Eastern [EH] and Western Hemisphere [WH]) tested the hypothesis that asenapine is superior to olanzapine for persistent negative symptoms of schizophrenia; 26-week extension studies assessed the comparative long-term efficacy and safety of these agents. In the core studies, 949 people were randomized to asenapine (n = 241 and 244) or olanzapine (n = 240 and 224); 26-week completion rates with asenapine were 64.7% and 49.6% (olanzapine, 80.4… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS